NCT05929235 2026-01-30
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Flare Therapeutics Inc.
Phase 1 Recruiting
Flare Therapeutics Inc.
Fujifilm Pharmaceuticals U.S.A., Inc.
Medical University of Vienna
Mabwell (Shanghai) Bioscience Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd.
Mabwell (Shanghai) Bioscience Co., Ltd.